LB Pharmaceuticals (LBRX)
Develops LB-102 for schizophrenia, bipolar depression, and related neuropsychiatric disorders.
$51.00
Pre-market+1.56 (+3.16%)
At close$49.44(+4.97%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions117 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 104.45% | 29.95M shares | |
| Adds to | 104.45% |
28.68M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 104.45%; nothing is left for Other.
Institutions13F, as of Jun 30, 2026
117 holders · 29.95M shares · 45 new positions · 86 increased · 13 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.35M | 11.69% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.73M | 9.53% | +263.5K | Aug 7, 2026 |
| Ra Capital Management, L.P. | 2.21M | 7.70% | 0 | Aug 14, 2026 |
| Trails Edge Capital Partners, LP | 1.52M | 5.31% | +203.7K | Aug 14, 2026 |
| Commodore Capital LP | 1.50M | 5.23% | 0 | Aug 14, 2026 |
| JPMorgan Chase & Co | 1.50M | 5.22% | +69.7K | Aug 12, 2026 |
| TCG Crossover Management, LLC | 1.45M | 5.05% | −392.2K | Aug 14, 2026 |
| Caligan Partners LP | 1.44M | 5.01% | 0 | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.